No products in the cart.
Pre-made Talacotuzumab benchmark antibody ( Whole mAb, anti-IL3RA therapeutic antibody, Anti-IL3R/CD123/IL3RX/IL3RY/hIL-3Ra Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-545
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Talacotuzumab biosimilar, Whole mAb, Anti-IL3RA Antibody: Anti-IL3R/CD123/IL3RX/IL3RY/hIL-3Ra therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
A humanized IgG1 monoclonal antibody against CD123 (Interleukin-3 receptor alpha chain or IL3RA) with potential antineoplastic activity. Upon intravenous administration, talacotuzumab binds to and neutralizes CD123.
| Products Name (INN Index) | Pre-Made Talacotuzumab biosimilar, Whole mAb, Anti-IL3RA Antibody: Anti-IL3R/CD123/IL3RX/IL3RY/hIL-3Ra therapeutic antibody |
|---|---|
| INN Name | Talacotuzumab |
| Target | IL3RA |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | 4jzj:HL:AB |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | CSL,Janssen Biotech |
| Conditions Approved | NA |
| Conditions Active | Myelodysplastic syndromes |
| Conditions Discontinued | Acute myeloid leukaemia,Systemic lupus erythematosus |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | IL3RA |
| Package |
Previous slide
Next slide
